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Abstract
Exposure to naturally occurring inorganic arsenic (iAs), primarily from contaminated drinking
water, is considered one of the top environmental health threats worldwide. Arsenic (+3 oxidation
state) methyltransferase (AS3MT) is the key enzyme in the biotransformation pathway of iAs.
AS3MT catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to trivalent
arsenicals, resulting in the production of methylated (MAs) and dimethylated arsenicals (DMAs).
MAs is a susceptibility factor for iAs-induced toxicity. In this study, we evaluated the association
of the polymorphism in AS3MT gene with iAs metabolism and with the presence of arsenic (As)
premalignant skin lesions. This is a case-control study of 71 cases with skin lesions and 51
controls without skin lesions recruited from a iAs endemic area in Mexico. We measured urinary
As metabolites, differentiating the trivalent and pentavalent arsenical species, using the hydride
generation atomic absorption spectrometry. In addition, the study subjects were genotyped to
analyze three single nucleotide polymorphisms (SNPs), A-477G, T14458C (nonsynonymus SNP;
Met287Thr), and T35587C, in the AS3MT gene. We compared the frequencies of the AS3MT
alleles, genotypes, and haplotypes in individuals with and without skin lesions. Marginal
differences in the frequencies of the Met287Thr genotype were identified between individuals
with and without premalignant skin lesions (p=0.055): individuals carrying the C (TC+CC) allele
(Thr) were at risk [odds ratio=4.28; 95% confidence interval (1.0–18.5)]. Also, individuals with C
allele of Met287Thr displayed greater percentage of MAs in urine and decrease in the percentage
of DMAs. These findings indicate that Met287Thr influences the susceptibility to premalignant As
skin lesions and might be at increased risk for other adverse health effects of iAs exposure.
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Human exposure to inorganic arsenic (iAs) occurs through its use in industry and
agriculture; however, the natural occurrence of iAs in drinking water is a serious concern
worldwide, particularly in low-income countries (IARC, 2004). In Mexico, several
provinces have been reported to have drinking water containing arsenic (As) at
concentrations higher than 10 μg/l, which is the maximum guideline value recommended by
the World Health Organization (WHO, 2003).
The urine of people exposed to iAs contains trivalent and pentavalent iAs metabolites:
monomethyl-As (MAs) and dimethyl-As (DMAs) (Valenzuela et al., 2005; Thomas et al.,
2007). Before being excreted in the urine, iAs undergoes a series of reductions of the
pentavalent species to the trivalent species followed by oxidative methylation to yield
pentavalent methylated species. The methylation of iAs is catalyzed by arsenic (+3 oxidation
state) methyltransferase (AS3MT), with S-adenosyl-L-methionine (SAM) serving as the
donor of a methyl group (Waters et al., 2004; Thomas et al., 2007). In humans,
biomethylation of iAs generally stops at the production of pentavalent and trivalent dimethyl
arsenical (DMAsV and DMAsIII). In addition, a sulfur-containing derivative of DMAsV,
dimethylthioarsinic acid (DMTA), has recently been found in urine of residents in
arseniasis-endemic areas of Bangladesh (Raml et al. 2007). However, in some individuals
with low exposures to iAs, the biomethylation process may proceeds further to form
trimethylar-senicals, mainly trimethylarsine oxide (TMAO) (Thomas, 2007). There is a large
variation in the metabolism of iAs between species, human populations, and individuals.
Most experimental animals methylate As efficiently to DMAs with essentially no MAs
excretion and a faster overall excretion of As than humans (Vahter, 2002). Efforts have been
made to characterize the toxic and carcinogenic effects of arsenicals and their metabolites. It
has been demonstrated that individuals with greater proportions of MAs in urine, which are
apparently due to a higher production of MAs in their tissues (Vahter, 1999), bare a higher
risk of adverse health effects, such as skin lesions and bladder cancer (Del Razo et al., 1997;
Yu et al., 2000; Valenzuela et al., 2005; Steinmaus et al., 2006). Moreover, we previously
reported that the urinary MAs in urine of these individuals are mainly in the trivalent
oxidation state (Valenzuela et al., 2005). Human and rodent studies have indicated that
chronic exposures to iAs are linked to several adverse health effects, including different
forms of cancer (Chen et al., 2003; Pu et al; 2007; Liu and Waalkes, 2008). Based on these
studies, iAs and its metabolites may act as complete carcinogens, co-carcinogens, or tumor
promoters/progressors (Kitchin, 2001; Rossman, 2003). Also, As may trigger vascular
disease, immunodepressed status, neurological effects, or diabetes mellitus (NRC, 2001;
IARC, 2004).
Epidemiologic studies have linked chronic exposure to iAs to increased risks of
premalignant skin lesions, such as hyperkeratosis on the palms and soles or
hyperpigmentation combined with small areas of hypopigmentation on the neck and back
(NRC, 2001; Centeno et al., 2002). These skin lesions have been used as a bio-marker of
chronic exposure to iAs (Chen et al., 2006). However, the occurrence of these skin lesions
varies among exposed individuals, suggesting that the susceptibility is determined in part by
genetic differences (Vahter, 2000).
The AS3MT gene, which is located in the chromosome 10q24.32 region and is comprised of
10 introns and 11 exons, has many polymorphic sites (Lin et al., 2002; Meza et al., 2005;
Wood et al., 2006). The –477 (A→G) transition variant may be implicated in iAs
metabolism because it is located 477 base pairs upstream from exon 1 in the promoter region
(Wood et al., 2006). This polymorphism may be associated with the expression of the
AS3MT gene, and in its turn, the amount of enzyme produced. A second relatively common
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polymorphism is 35587 (T→C), which is located in intron 10 and results in a decreased
relative proportion of MAs in the urine. This polymorphism is expected to be associated
with a lower risk of adverse health effects following As exposure (Meza et al., 2007). The
exonic Met287Thr (T→C) polymorphism is associated with high AS3MT activity and
increased production of MAs in in vitro studies (Drobná et al., 2004; Wood et al., 2006).
Furthermore, epidemiological studies of a European population (Lindberg et al., 2007) and a
Chilean group (Hernandez et al., 2008) have shown that individuals carrying the C allele
(Thr287) excrete a higher percentage of MAs in their urine.
To date, little is known about the association of the AS3MT polymorphism and the adverse
health effects caused by chronic iAs exposure. Clearly, more data is needed to better
understand the role of AS3MT polymorphism as a susceptibility marker in human
populations. In the present study, we hypothesized that common AS3MT polymorphisms
affect As biomethylation, mainly the production of trivalent As metabolites. Additionally,




Arsenic acid, disodium salt, (Na2HAsVO4; > 99% pure), sodium m-arsenite (NaAsIIIO2; >
99% pure), and dimethylarsinic acid [DMAsV; (CH3)2AsVO(OH); 98% pure] were obtained
from Sigma Chemical Co. (St. Louis, MO, USA). Methylarsonic acid (MAsV), disodium
salt, [CH3AsVO (ONa)2; 99% pure] was obtained from Ventron (Danvers, MA). The
trivalent methylated arsenicals, methyloxoarsine (MAsIIIO; CH3AsIIIO) and
iododimethylarsine of DMAsIII [DMAsIII; (CH3)2AsIII], were synthesized by W. R. Cullen
(University of British Columbia, Vancouver, Canada) using previously described methods
(Stýblo et al., 1997). Working standards of these arsenicals, which contained 1 μg of As/ml,
were prepared daily from stock solutions. Sodium borohydride (NaBH4) was obtained from
EM Science (Gibbstown, NJ, USA). Tris hydrochloride was purchased from J. T. Baker
(Phillipsburg, NJ, USA). Creatinine kits were purchased from Randox (San Diego, CA,
USA). All other chemicals used were at least analytical grade. Standard reference material
(SRM) water (SRM 1643e) and urine [SRM 2670; National Institute of Standards and
Technology (NIST), Gaithersburg, MD] were used for quality control of total arsenic (TAs)
measurements in water and for urine analyses, respectively.
Selection of study participants
In a cross sectional, case-control study was carried out in a total of 122 residents of
Zimapan, Hidalgo (Mexico), all of Hispanic origin, were included. They were recruited for a
baseline visit, where one hundred and forty people were invited, 15 refused to participate
(10.7%) and 3 were excluded because they did not attend the appointment for urine
collection. In Zimapan-endemic region, long-term iAs exposure has been recorded since
1992. The concentrations of iAs in wells and the potable supply was as high as to 1100 μg
As/l. In 1999 the most contaminated well was closed by the local authorities, and the mean
of iAs concentration in water decreased significantly; however, the iAs concentration in this
region is still significantly higher than the recommended value 10 μg As/l for drinking
water, with mean values of 110 μg iAs/l (Valenzuela et al., 2007). Subjects were recruited
through door-to-door contact. They had to be at least 15 years old and had to be living in the
town for the previous 2 years. Participants were recruited between January and March 2006.
The ethnicities were determined through questionnaire and required both parents and all
grandparents to be of the same ethnicity as the subject. Water, urine, and buccal cells were
collected. Additionally, the As-induced skin lesion status was evaluated, quantified, and
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validated by our study physicians and expert dermatologists. As-related skin lesions are
known to be a hallmark of chronic iAs poisoning. These lesions include alterations in
pigmentation and discoloration of skin, and in many cases, these symptoms are accompanied
by keratosis, the thickening of the skin of the palms, soles and trunk (Yeh, 1973). The
clinical examination protocols used to assess skin lesions were previously described
(Valenzuela et al., 2005). The study physicians were not aware of the level of As in the
participants’ drinking water supplies. They identified 71 individuals with As skin lesions
(case) and 51 without As skin lesions (control). The final decision for eligibility of
participant in this study was based on to have one group of individuals (approximately 50%)
presenting at least one skin sign of arseniasis, such as hypo/hyperpigmentation,
palmoplantar hyperkeratosis and ulcerative lesions as described by Yeh (1973). The
protocols used in this study were approved by the Institutional Committee at Cinvestav-IPN,
and written informed consent was obtained from all participants in the study.
Sample collection, storage, and processing
Water sample collection and As assay—Water samples were collected from the wells
used by the study participants in 15-ml acid-washed tubes and stored at −20 °C until they
were assayed. A detailed description of the water-collection procedure has been reported
previously (Valenzuela et al., 2007). Total As (TAs) concentrations were measured as
previously described (Del Razo et al., 1990) by hydride generation-atomic absorption
spectrometry (HG-AAS) using a Perkin Elmer 3100 spectrophotometer (Perkin Elmer,
Norwalk, CT, USA) equipped with a FIAS-200 flow injection atomic spectroscopy system.
SRM 1643e was used for quality control during the analyses of TAs in water. The certified
TAs concentration in SRM 1643e is 60.45± 0.72 μg/l. The value determined in our
laboratory, 61.3±0.68 μg/l (n=3) is in good agreement with the certified value.
Urine sample collection and As speciation analysis—Spot urine samples were
collected in 100 ml acid-washed bottles. A detailed description of the urine collection
procedure has been reported elsewhere (Valenzuela et al., 2007). The collected urines were
aliquoted to 15 ml plastic tubes and shipped on dry ice to our analytical laboratory at
Cinvestav-IPN, Mexico City. The trivalent As species were analyzed within 6 h of
collection.
All urinary metabolites of As (iAsV, iAsIII, MAsV, MAsIII, DMAsV, and DMAsIII) were
measured by a pH-specific HG-AAS, using cryotrapping (CT) for preconcentration and
separation of arsines (Del Razo et al. 2001; Devesa et al., 2004). The TAs value was
calculated as the sum of the iAsV, iAsIII, MAsV, MAsIII, DMAsV, and DMAsIII. We used
the SMR 2670 with the certified As content of 480±100 μg/l to validate the calculated TAs
in urine samples with high As concentrations. The low-As urine SRM 2670 with a reference
value of 60 μg/l was used to validate analyses of urines with low levels of As. Triplicate
measurements of the high and low SMR standards using pH-specific HG-AAS provided the
values of 507±17 μg/l and 64±5 μg/l, respectively.
Because trivalent methylated arsenicals rapidly oxidize, only 10 to 12 urine samples were
analyzed each time. Quality assurance included the measurement recovery of fresh prepared
methylated trivalent standard (10 ng for MAsIII and 20 ng of DMAsIII), analyzed in
duplicate for each analytical batch. Recoveries ranged from 88 to 101% with a variation
coefficient between 0.5 and 13%. The As species were measured from spot urine samples
and were thus dependent on urine dilution. To correct for differences in urine dilution, the
urinary As species were adjusted for urinary creatinine. This parameter was measured by the
Jaffe reaction using a Randox commercial kit.
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Buccal cell collection and DNA extraction—Buccal cells were collected with a
cytobrush. All participants were instructed to brush their teeth and refrain from eating and
drinking for at least 1 h before sample collection. Subjects had each cheek brushed for at
least 30 s. Each brush was then placed in a 15 ml sterile plastic tube. Genomic DNA was
isolated from the buccal cell samples using a commercial DNA purification kit according to
the manufacturer’s protocol (Amersham GFX Genomic blood, Amersham Pharmacia
Biotech Inc., Uppsala, Sweden). The DNA concentration and purity were evaluated by the
ratio of absorbances at 260 and 280 nm (range obtained was 1.6 to 1.8). DNA quality was
assessed after separation by the ethidium bromide agarose-gel electrophoresis.
TaqMan SNP assays—We have genotyped three single nucleotide polymorphic sites
(SNPs; A-477G, Met287Thr and T35587C) in the AS3MTgene. Quantitative real-time PCR
assays (rtPCR) were performed with gene-specific fluorescent labeled probes in a PCR ABI
Prism 7000 Sequence Detector using TaqMan Universal PCR Master Mix (Applied
Biosystems; Foster City, CA, USA). The probes were labeled with 6-carboxyfluorescein and
VIC as the 5′-fluorescent reporter. Nonfluorescent quenchers were designed at the 3′-end of
the probes using Primer Express software (Applied Biosystems) and are listed in Table 1.
The TaqMan genotyping assay was performed according to the manufacturer’s protocol in a
total volume of 20 μl per single tube reaction. In each assay, DNase-free water was used as
nontemplate control and DNA with a known AS3MT genotypes were used as a positive
control. Assay conditions were 2 min at 50 °C, 10 min at 95 °C, and 40 cycles of 95 °C for
15 s and 60 °C for 1 min. The SNP assay was set up using the Sequence Detection System
(SDS), version 2.1 (Applied Biosystems) as an absolute quantification assay, and after the
assay was completed, the plate was read using allelic discrimination settings.
Indicators of As exposure and metabolism
Cumulative As exposure—Each study subject was interviewed to assess individual
exposures to As in drinking water. Information about the current and past sources and daily
amounts of drinking water was recorder. If the previously used water well was within the
study area and the As concentration was known, the As concentration of the previously used
well was incorporated into the calculation of the cumulative As exposure or time-weighted
exposure (TWE). TWE was calculated for each participant as sum of the products of the
amount of water consumed per day (l/day), As concentration in water in each well (mg/l),
and time during which water from each well was used (days) (Valenzuela et al., 2005). The
TWE is a good indicator of long-term As exposure (Del Razo et al., 1997).
Indicators of As metabolism—The percentages of iAs, MAs, and DMAs in urine were
calculated. An alternative method for describing As metabolism employed the primary
(MAs/iAs) and secondary (DMAs/MAs) methylation ratios. Moreover, we calculated the
percentages of iAs, MAs, and DMAs in trivalent and pentavalent oxidation states.
Statistical analysis—The Hardy–Weinberg equilibrium was evaluated for each SNPs
using data from all participants within each group using a Bonferroni-corrected threshold
(Duggal et al., 2008). No SNPs were found to violate the Hardy–Weinberg equilibrium.
Arsenical values were transformed to a log scale in order to calculate means and range, to
perform statistical comparisons between groups and to evaluate potential confounding
factors. Differences in the percentages of urinary As species and the species ratios between
each genetic polymorphism were evaluated by Student t-test. Multiple comparisons between
groups were made using one-way repeated-measures ANOVA in case of a normal
distribution of the data or using a χ2 test otherwise. Post hoc analysis was made using the
Holm–Sidak t-test for pair-wise comparisons. We used unconditional logistic regression
analyses to examine associations between each genetic polymorphism and each phenotype.
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The comparisons performed were: 1) Non-lesion vs. lesion, 2) stratified by genotype, 3)
stratified by haplotypes. Each polymorphism was modeled individually as gene-effects in
logistic regression models, and the odds ratios (OR), and 95% confidence intervals were
estimated. Pair-wise interactions among all independent SNPs were tested using logistic
regression. All analyses were adjusted for age, gender and the TWE, but possible risk factors
(alcohol use) was excluded as confounders because they were independent of the studied
variables. As shown previously, haplotype information may be more useful than individual
polymorphisms in association studies (Brodde and Leineweber, 2005). Therefore, we also
performed haplotype analyses for the three AS3MT SNPs. Three participants were excluded
from the haplotypes association analyses because of the lack of A-477G SNP information.
Statistical significance was defined as a p-value <0.05. All statistical analyses were
performed using STATA for Windows, version 9.0 (Stata, Corp., College Station, TX,
USA).
Results
A total of 13 males and 109 females were included in the study. The number of male
participants in our study was very low due to the high migration of males to USA. The age
range was 18–50 years, and the participants were on average 35 years old. The majority
(58.2%) of the study population had As-skin lesions. The main population characteristics,
stratified by the presence (n=71) or absence (n=51) of As-skin lesions are shown in Table 2.
The As-skin lesions group had higher levels of TAs in urine [median and range; 94.3 (12.5–
1398) vs 40.6 (9.8–62.9) μg/g creatinine; p<0.05], TAs in water [104 (29–378) vs 12 (9–45)
μg/l; p<0.05] than the group without skin lesion.
The effects of two AS3MT polymorphisms (A-477G SNPs in promoter region, T35587C
SNPs in intron 10, and exonic T14458C) on As metabolism of all study participants are
shown in Table 3 and Fig. 1. The median As concentrations in urine and well water of all the
individuals studied were 109 μg/g creatinine and 84 μg/l, respectively. It is known that the
creatinine level in urine of males is generally higher than that of females because its
excretion into the urine is related to mass of muscle. However, no significant difference was
observed for creatinine between males and females in this study (data no shown).
The efficiency of As methylation was assessed by calculating the ratio between the urinary
concentrations of the product and the substrate; higher values represent a higher methylation
capacity (Del Razo et al., 1997). Individuals carrying the G allele in the A-477G variant had
the lowest proportion of MAs and the highest proportion of DMAs, which consequently
increased the DMAs/MAs ratio (Tables 3 and 4). Evaluation of Met287Thr polymorphism
showed that the percentages of iAs and MAs were higher in individuals with the C allele
(287Thr variant) than in those with the T allele (Met287). Also, the DMAs proportions were
lower in individuals carrying the C allele than in those carrying the T allele (Tables 3 and 4).
Our results showed no differences in the MAs/iAs ratio between the evaluated SNPs. A
statistically significant difference was observed in the DMAs/MAs ratio for individuals with
the Met287Thr polymorphism; individuals with the TC/CC variant had the ratio equal to 9.4,
while those with the TT variant had the ratio equal to 6.1. These results indicate that the
second methylation step may be less efficient in people carrying the 287Thr variant (Table
3).
We have observed effects of the AS3MT polymorphism (A-477G and Met287Thr) on the
urinary concentrations of both trivalent and pentavalent As species (Fig. 1; Table 3). No
difference was found in the relative proportions of pentavalent arsenicals in relation to the
A-477G and T35587C variants. However, individuals with Met287Thr variants showed
statistically significant differences in the percentage of MAsIII+V in urine (Table 3). For the
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trivalent arsenicals, iAsIlI, MAsIII, and DMAsIII, individuals with the mutant homozygous
(GG) genotype in the promoter variant (−477) had a lower proportion of iAsIII than
homozygotes AA variants and heterozygotes AG variants (Fig. 1). Furthermore, in urine of
individuals with the exonic genetic variant (Met287Thr), the percentage of MAsIII was
significantly higher in mutant homozygote (only one individual) (CC) and heterozygotes
(TC) than in normal homozygotes (TT). Individuals heterozygous or homozygous for the
Met287Thr variant (C allele) had a lower percentage of DMAsIII than wild-type
homozygotes (p<0.05). The effects of AS3MT polymorphisms on urinary As metabolism
observed in total group (Table 3), remained for Met287Thr even after stratifying the groups
according to presence of As-skin lesions (Table 4).
The distribution of AS3MT polymorphism among individuals with and without skin lesions
is shown in Table 5. Marginal differences in the frequencies of the Met287Thr genotype
were identified between individuals with and without premalignant skin lesions (p=0.055).
These results suggest that the formation of premalignant As-skin lesions could be related to
Met287Thr genotype, individuals carrying the C allele (TC+CC) were at risk [OR=4.28;
95%CI (1–18.5)]. The occurrence of A-477G and T35587C SNPs did not differ between the
two study groups, suggesting that these polymorphic variant are not associated with the risk
of As-skin lesions (Table 5). However, the A-477G polymorphism was associated with
differences in the DMAs/MAs ratio in urine (Table 3 and 4).
Haplotypes analyses
The results of the haplotype analyses for AS3MT are shown in Tables 6 and 7. Haplotype 3
(ACT) was associated with an increase in the percentage of urinary MAs and decrease in the
percentage of DMAs as compared to the haplotypes 1, 2, and 4. However, these differences
are mainly associated with the proportion of the methylated trivalent arsenicals (MAsIII and
DMAsIII), with the strongest effect for the percentage of MAsIII. The percentage of iAsV
followed a pattern similar to that of MAsIII percentage for the ACT haplotype. Haplotype 3
had a higher percentage of iAsV (14.5) than haplotypes 1, 2 and, 4 (9.2%, 8.8%, and 8.0%,
respectively). No differences were observed in the MAs/iAs ratios or the DMAs/MAs ratios.
For our multivariate analyses, we designed one model for each haplotype formed by a
combination of the A-477G, Met287Thr and T35587C genetic variants in AS3MT. Table 8
shows the results of the multiple logistic regression analyses stratified by the presence of
cutaneous signs indicating the relation of haplotypes evaluated with the presence of As
premalignant skin lesions. We tested whether As-skin lesions were influenced by
polymorphisms in the AS3MT gene. Because, gender, age, and TWE are associated with the
presence of As-skin lesions, we included these confounding variables in the multivariate
analyses. No significant interactions were found between AS3MT and TAs in urine or with
TWE. The multivariate models for carriers of the haplotypes 3 and 6 showed a high
frequency in individuals with skin lesions (9% and 13%, respectively), but possibly due to
the small size of each haplotype group. The association was not statistically significant. We
only observed a marginal association of haplotype 3 carriers bearing a greater risk of
developing premalignant skin lesions from As exposure following adjustments for age,
gender and TWE (OR=4.56, p=0.09). The model for haplotype 3 showed that carrying
mutant allele C in position (i.e., Thr287) was the most important determinant of presence of
As-skin lesions. In contrast, the haplotype 4 carriers of mutant allele of 35587C had a lower
risk of arsenic skin lesions (OR=0.65), which is similar to what we observed for haplotype 1
(OR =0.62), although these results were not statistically significant (Table 8).
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This study including individual exposure assessment and inclusion of trivalent and
pentavalent arsenic species in human urine, in order to determine a possible metabolite
causal of iAs effects on arsenic-skin lesions. Importantly in this study, we found multivariate
associations among the urinary As species with AS3MT genotyping after adjusting to age,
gender and TWE. Marginal significant differences in the frequencies of the Met287Thr
genotype were identified between individuals with and without premalignant skin lesions
(p=0.055). These results suggest that the formation of premalignant As-skin lesions could be
related to Met287Thr genotype.
Although differences in responses among individuals can be attributed to differences in
cumulative dosage or the duration of exposure, variations in responses may also reflect
inter-individual differences in the kinetic behavior and dynamic effects of the As species
that initiate and/or promote disease processes. The variability in the patterns of urinary
metabolites from exposed humans may reflect differences in the production or tissue
retention of critical metabolites. There is a marked inter-individual variability in the effects
of iAs exposure in terms of carcinogenesis and other health outcomes among exposed
populations (Hughes et al., 2007).
Various genetic and toxicological endpoints have been used as biomarkers to understand the
biological effects of iAs exposure. Recently, evidence from epidemiological studies has
consistently demonstrated a relationship between altered urinary arsenic metabolite profiles
and polymorphisms in genes implicated in iAs metabolism (Lindberg et al., 2007;
Hernandez et al., 2008).
Genetic factors are involved in the development of premalignant skin lesions due to iAs
exposure. Recent advances in SNP genotyping methods have enabled the detection of
genetic variations associated with increased susceptibility to As-induced skin lesions.
Previous studies have identified genetic variations in glutathione S-transferase (GST),
myeloperoxidase (MPO), catalase (CAT), tumor suppressor protein 53 (p53), xeroderma
pigmentosum group D (XPD) and X-ray repair cross-complementing group 1 (XRCC1) that
are associated with As-induced skin lesions (Ahsan et al., 2003; De Chaudhuri et al., 2006;
Banerjee et al., 2007; Breton et al., 2007; McCarty et al., 2007). These identified genes are
related to cellular glutathione levels, oxidative stress, the nucleotide excision repair
pathway, control of cell growth or maintenance of genomic stability. We have examined
three SNPs in AS3MT gene and found that the Thr287 variant is associated with risk of As-
premalignant skin lesions. The frequency of C allele (i.e., Thr287) was higher among the
individuals with skin lesions as compared to the individuals without skin lesions. In contrast
with our findings are results of an independent study which showed no association between
the Thr287 variant and As-skin lesions in an Indian population exposed to iAs in drinking
water. Notably, the frequency of heterozygosity (the TC genetic variant) in this population
(9%) (De Chaudhuri et al., 2008) resembled the frequency found in our study.
The mechanism by which this polymorphic site affects development of premalignant skin
lesions is not clear. However our results together with results of other studies (Lindberg et
al., 2007) suggest that the formation of premalignant As-skin lesions is related to iAs
metabolism. All human studies that examined the association between As metabolic
phenotypes and disease found that individuals with disease manifestations had relatively
higher urinary levels or percentage of MAs as compared to individuals without health
problems (Del Razo et al., 1997; Valenzuela et al., 2005; Steinmaus et al., 2006). The HG-
CT-AAS analytical method used in the present study examined only the HG-active tri- and
pentavalent iAs, MAs, and DMAs formed in the process of AS3MT-catalyzed methylation.
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TMAsVO also is able to be analyzed using this methodology, but as we found low
concentration of TMAsVO (<8 ng/l) in the urine of only 4 participants; In consequence,
TMAsVO was not considered within the methylation profile of the participants of this study.
Other possible HG arsenic form in urine is DMTA (Raml et al. 2007) but it does not
significantly interfere with analysis of DMAsIII and/or DMAsV (Hernández-Zavala et al.,
2008; Matoušek et al 2008). Therefore, the risk of underestimating or misidentifying DMAs
in the present study is minimal.
We examined iAs metabolic phenotypes, including the concentrations and proportions of the
trivalent and pentavalent As species in the urine We found that the Thr287 variant was
associated with an increased percentage of MAsIII and a decreased percentage of DMAsIII in
urine. These results are in a good agreement with studies carried out in European and
Chilean populations (Lindberg et al., 2007; Hernandez et al., 2008).
The Met287Thr polymorphism is a nonsynonymous base-pair substitution, which suggests
that the alterations at the genomic levels change the biophysical and biochemical properties
of the corresponding AS3MT protein. The impact of the Met287Thr polymorphism on the
expression and function of AS3MT was recently examined using a primary culture of human
hepatocytes exposed to different concentrations of iAsIII. The variant Met287Thr
heterozygotes (TC variant) had lower percentage of DMAs and a higher percentage of MAs
than the wild-type (TT variant) when exposed to iAsIII (Drobná et al., 2004). Moreover,
Wood et al. (2006) have shown that the Thr287 variant expressed in COS-1 cells had higher
enzymatic activity and increased protein expression than the Met287 variant.
Additionally, several AS3MT polymorphism in intronic regions have been associated with
different urinary arsenic patterns in various ethnic groups, including Argentinean, Mexican
and European populations (Lindberg et al., 2007; Meza et al., 2007; Rahman et al., 2007).
These studies have shown that the 12390C and 35587C AS3MT variants had lower
percentages of MAs and higher DMAs/MAs ratios. To date, the functional role of SNPs in
AS3MT introns remains unclear. One possible explanation is that the AS3MT T35587C
variant in intron 10 results in an alternatively spliced form of AS3MT mRNA, which loses
the capacity for As methylation to the MAs form resulting in a decreased proportion of
urinary MAs (Meza et al., 2007).
We demonstrated that the A-477G allele frequencies in studied Mexican population is 38%,
which is consistent with that of other researchers studying Caucasian-American populations
(Wood et al., 2006). No previous study examined this polymorphic site with respect to iAs
metabolism. In our study, we found that people carrying the homozygous –477 (GG) mutant
alleles had a lower percentage of MAs, a higher percentage of DMAs, and consequently had
a higher DMAs/MAs ratio. The relationship between the As phenotype and the A-477G
polymorphism may result from a genetic background effect or from its location in the
promoter region of the AS3MT gene. Possibly, A-477G is part of an enhancer site that
contributes to the gene expression.
Despite the lack of statistical association between the AS3MT haplotypes and iAs-induced
skin lesions in this study, we should not overlook the haplotype 3 (ACT) that can be
considered as a biomarker candidate for risk of premalignant skin lesions in populations
exposed to iAs. The lack of significant associations and statistical power in our study was in
part due to the small sample size in each of the haplotype groups we evaluated. Additionally,
it was not possible to perfectly match gender, age, and TWE factors between individuals in
with and without skin lesions. Nevertheless, the calculated power analysis to detect a
significant association between groups with (58.2%) and without skin lesions (41.8%) at the
alpha=0.05 level, with 122 participants, was good (0.73). Some limitations include the
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relatively small sample size, and the data for the men were limited, thus precluding us from
analyzing whether there were any sex differences in gene–As interactions for risk of As-
related skin lesions. Our samples were collected in central Mexico, where the population is
represented by a mixture of American Indians, Caucasians and African Americans.
Therefore, the genetic background of the study population is less homogeneous than in
studies of Asian or European populations. This heterogeneity may have influenced the
results of our association analysis. Previously, researchers identified a significant association
between the Met287Thr polymorphism and the urinary level of MAs (Hernandez et al.,
2008). The high proportions of MAs in urine are known risk factor for several adverse
effects and diseases caused by iAs exposure (Ahsan et al., 2007; McCarty et al., 2007;
Tseng, 2007). Our findings suggest that along with these risks, there is also an association
between 287Thr and As-skin lesions.
Because trivalent methylated arsenicals rapidly oxidize, storage conditions may significantly
affect results of urine speciation (Del Razo et al., 2001; Gong et al., 2001). Future studies
evaluating methylated trivalent As species in the urine should consider an immediate
analysis of fresh urine samples, preventing the oxidation of unstable methylated AsIII-
containing metabolites.
This is the first study that indicates an association between AS3MT polymorphism and As-
induced skin lesions. Our findings indicate that AS3MT polymorphism contributes to the
etiology of premalignant skin lesions associated with chronic exposure to iAs. However,
further studies are needed to clarify this association.
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The relative proportions of trivalent arsenic metabolites in urine of individuals with different
AS3MT SNPs: A477G (n=119), Met287Thr and T35587C polymorphisms sites, stratified by
genotype (n=122). (AA) homozygous wild-type, (AG) heterozygous, (GG) mutant
homozygous in the case of A-477G genetic variant. (TT) homozygous wild-type, (TC)
heterozygous, (CC) mutant homozygous for Met287Thr and T35587C SNPs. Values are
expressed as the mean±SEM of urinary proportion of iAsIII (A), MAsIII (B), and DMAsIII
(C). *p<0.05 using the Student t-test.
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Table 2
Demographic and descriptive statistics of the study population.
Variable Non skin lesion With skin lesion
N (%) N (%)
Age (years)
<35 24 (47) 36 (51)
≥35 27 (53) 35 (49)
Gender
Male 4 (8) 9 (13)
Female 47 (92) 62 (87)
Drinking status
Alcohol consumption
Drinker 7 (14) 14 (20)
Non-drinker 44 (86) 57 (80)
TAs in water (μg/l)
≤10 34 (67) 8 (11)
>10 17 (33) 63 (89)
TAs in urine (μg/g creatinine)
≤50 25 (49) 17 (24)
>50 26 (51) 54 (76)
Time-weight of exposure (mg/years)
≤1 35 (69) 3 (4)
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Table 6
AS3MT haplotypes and frequencies in the Study population.
Haplotypes Frequency
1 –477A/287T/35587T (ATT) 0.84
2 –477G/287T/35587T (GTT) 0.60
3 –477A/287C/35587T (ACT) 0.076
4 –477A/287T/35587C (ATC) 0.28
5 –477A/287C/35587C (ACC) 0.008
6 –477G/287C/35587T (GCT) 0.11
7 –477G/287C/35587C (GCC) 0.042
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